AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7075639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31876118 — intervention group
Group type: EXPERIMENTAL
Intervention: nano-hydrogel embedded with quercetin and oleic acid
Number of subjects: 56
Study 31876118 — intervention group
Group type: COMPARATOR
Intervention: hyaluronic acid (0.2%)
Number of subjects: 56
Study 29935939 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ∆9‐THC administration
Number of subjects: 24
Study 29935939 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study 29935939 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ∆9‐THC administration in non‐users
Number of subjects: 24
Study 29935939 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in cannabis users
Number of subjects: 24
Study 26909743 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (294 mg per day as micelles)
Number of subjects: 42
Study 26909743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25057209 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic spines in adult human neocortex
Number of subjects: 500
Study 23379240 — intervention group
Group type: EXPERIMENTAL
Intervention: Afala, 2 tablets 4 times a day for 6 months
Number of subjects: 94
Study 20702792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cardiovascular disease (CVD)
Number of subjects: 292
Study 20702792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CVD, hypercholesterolemia, hypertension
Number of subjects: 292
Study 20702792 — intervention group
Group type: COMPARATOR
Intervention: Conventional HAD risk factors and CNS penetration effectiveness rank of antiretroviral regimens
Number of subjects: 292
Study 20702792 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive impairment
Number of subjects: 292
Study 20702792 — intervention group
Group type: EXPERIMENTAL
Intervention: QNPZ-5 score
Number of subjects: 292
Study 18359717 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of nebulized budesonide suspension plus salbutamol and ipratropium bromide twice daily for 5 days (Group A)
Number of subjects: 113
Study 18359717 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus aminophylline injection once daily for 5 days (Group C)
Number of subjects: 113
Study 18359717 — intervention group
Group type: COMPARATOR
Intervention: Budesonide plus salbutamol and ipratropium aerosol (Group B)
Number of subjects: 113
Study 16242948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized iloprost (25 microg)
Number of subjects: 22
Study 16242948 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 22
Study 11855542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide
Number of subjects: 0
Study 11855542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9528844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (3 g m(‐2) x (2 or 3) days as a 1‐h bolus)
Number of subjects: 11
Study 9528844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (same total dose as continuous infusion)
Number of subjects: 11
Study 9528844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg 8 hourly for 3 days starting 8 h before IFOS (for two cycles)
Number of subjects: 11
Study 7598087 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint LI-4 (Hoku) stimulation
Number of subjects: 21
Study 7598087 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture point stimulation
Number of subjects: 21
Study 2650643 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision
Number of subjects: 85
Study 2650643 — intervention group
Group type: COMPARATOR
Intervention: Topical antimicrobial therapy and skin grafting after spontaneous eschar separation
Number of subjects: 85
Study 2650643 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision and topical antimicrobial therapy
Number of subjects: 85
Study 1159265 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (12 mg daily for two weeks)
Number of subjects: 40
Study 1159265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30987663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) supplementation (0.2 g/kg body mass)
Number of subjects: 20
Study 30987663 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HCO3--free beverage)
Number of subjects: 20
Study 26711938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth sectioning performed (Group B)
Number of subjects: 100
Study 26711938 — intervention group
Group type: COMPARATOR
Intervention: No tooth sectioning performed (Group A)
Number of subjects: 100
Study 24861133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg single oral dose) plus Cyclosporine (600 mg single oral dose)
Number of subjects: 26
Study 24861133 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor alone
Number of subjects: 26
Study 24861133 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 26
Study 22648712 — intervention group
Group type: COMPARATOR
Intervention: [¹³C]Palmitate and octanoate administered via gastrointestinal endoscopy
Number of subjects: 67
Study 22648712 — intervention group
Group type: COMPARATOR
Intervention: Portal-systemic shunt treatment in the PH(+)LC group
Number of subjects: 67
Study 22648712 — intervention group
Group type: COMPARATOR
Intervention: Intestinal specimens examination in PH(+)LC group
Number of subjects: 67
Study 22648712 — intervention group
Group type: COMPARATOR
Intervention: High serum concentrations of glucagon-like peptide-2 in PH(+)LC group
Number of subjects: 67
Study 20723619 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiGraph monitor
Number of subjects: 239
Study 20723619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study 18221433 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled-release alpha-lipoic acid (CRLA) for 3 months
Number of subjects: 40
Study 18221433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16318978 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dydrogesterone per day during the first trimester of pregnancy
Number of subjects: 20
Study 16318978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12629248 — intervention group
Group type: EXPERIMENTAL
Intervention: tau H1/H1 genotype
Number of subjects: 25
Study 12629248 — intervention group
Group type: COMPARATOR
Intervention: No mutations detected
Number of subjects: 25
Study 12569789 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-Du-Qing
Number of subjects: 0
Study 12569789 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1992214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d)
Number of subjects: 35
Study 1992214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1992214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin with low-fat diet
Number of subjects: 35
Study 1992214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin with high-fat diet
Number of subjects: 35
Study 1992214 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 35
Study 1992214 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 35
Study 6882816 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium sensitivity feedback
Number of subjects: 34
Study 6882816 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sensitivity feedback
Number of subjects: 34
Study 6882816 — intervention group
Group type: COMPARATOR
Intervention: High sensitivity feedback
Number of subjects: 34
Study 31417102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100 μg/25 μg or 200 μg/25 μg
Number of subjects: 400
Study 31417102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 400
Study 31417102 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 29656442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (24 mg/d on a 28-day cycle)
Number of subjects: 392
Study 29656442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 26756115 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin during euglycemic hyperinsulinemia
Number of subjects: 0
Study 26756115 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0
Study 26756115 — intervention group
Group type: EXPERIMENTAL
Intervention: METsYN subjects
Number of subjects: 0
Study 26756115 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and post-insulin clamp
Number of subjects: 0
Study 24216218 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning to formula containing hydrolyzed cow's milk protein
Number of subjects: 5000
Study 24216218 — intervention group
Group type: COMPARATOR
Intervention: Weaning to formula containing intact cow's milk protein
Number of subjects: 5000
Study 22167541 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost BAK-free
Number of subjects: 371
Study 22167541 — intervention group
Group type: COMPARATOR
Intervention: Travoprost BAK
Number of subjects: 371
Study 19907417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 60
Study 19907417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17613258 — intervention group
Group type: EXPERIMENTAL
Intervention: MT-BMSCs (bone marrow stromal cells)
Number of subjects: 0
Study 17613258 — intervention group
Group type: EXPERIMENTAL
Intervention: M-PCs (periosteal cells)
Number of subjects: 0
Study 17613258 — intervention group
Group type: EXPERIMENTAL
Intervention: MT-BMSCs and M-PCs
Number of subjects: 0
Study 15828852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg famotidine (single dose, intravenous or oral)
Number of subjects: 36
Study 15828852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg/dose intravenously or 0.5 mg/kg/dose orally (multiple doses)
Number of subjects: 36
Study 15828852 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/dose intravenously or 1 mg/kg/dose orally (subsequent doses)
Number of subjects: 36
Study 12135452 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient multicomponent training program including strength training
Number of subjects: 68
Study 12135452 — intervention group
Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 68
Study 10321172 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-Guide
Number of subjects: 40
Study 10321172 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidor
Number of subjects: 40
Study 8625185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic intraarterial chemotherapy (IAC) with mitomycin-C (10 mg/m2), vincristine (1 mg/m2), and cisplatin (50 mg/m2)
Number of subjects: 21
Study 8625185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic intraarterial chemotherapy (IAC) with mitomycin-C (10 mg/m2), vincristine (1 mg/m2), and cisplatin (75 mg/m2)
Number of subjects: 21
Study 8625185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic intraarterial chemotherapy (IAC) with cisplatin (75 mg/m2)
Number of subjects: 21
Study 8625185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic intraarterial chemotherapy (IAC)
Number of subjects: 21
Study 1852090 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (15 micrograms/kg/min for 24 hours)
Number of subjects: 20
Study 1852090 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (24-hour infusion)
Number of subjects: 20
Study 6154200 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 or 0.2 mg)
Number of subjects: 11
Study 6154200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30675700 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde biliary drainage (ERBD)
Number of subjects: 899
Study 30675700 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic cholangiography and drainage (PTCD)
Number of subjects: 899
Study 30675700 — intervention group
Group type: EXPERIMENTAL
Intervention: No preoperative biliary drainage (non-PBD)
Number of subjects: 899
Study 30675700 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 899
Study 28389510 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone for 24 weeks
Number of subjects: 58
Study 28389510 — intervention group
Group type: COMPARATOR
Intervention: LNCaP cells expressing SLCO2B1
Number of subjects: 58
Study 26923644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT)
Number of subjects: 31
Study 26923644 — intervention group
Group type: COMPARATOR
Intervention: Passive mobilization (Control)
Number of subjects: 31
Study 24518789 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef
Number of subjects: 15
Study 24518789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish
Number of subjects: 15
Study 24518789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken
Number of subjects: 15
Study 22945718 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + Prompt L‐Pop
Number of subjects: 60
Study 22945718 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion + phosphoric acid etching
Number of subjects: 60
Study 22945718 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching
Number of subjects: 60
Study 22945718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 60
Study 22945718 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + etching
Number of subjects: 60
Study 22945718 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion + Prompt L‐Pop
Number of subjects: 60
Study 19576277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium nitrite (0.12 mmol NaNO(2)/mmol Hb)
Number of subjects: 9
Study 19576277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium nitrite (0.06 mmol NaNO(2)/mmol Hb)
Number of subjects: 9
Study 19576277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite (0.12 mmol NaNO(2)/mmol Hb)
Number of subjects: 9
Study 17689624 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.625 mg
Number of subjects: 822
Study 17689624 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.625 mg and medroxyprogesterone acetate (MPA), 2.5 mg
Number of subjects: 822
Study 17689624 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.45 mg
Number of subjects: 822
Study 17689624 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.45 mg and medroxyprogesterone acetate (MPA), 2.5 mg
Number of subjects: 822
Study 17689624 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.45 mg and medroxyprogesterone acetate (MPA), 1.5 mg
Number of subjects: 822
Study 17689624 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.3 mg
Number of subjects: 822
Study 17689624 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE), 0.3 mg and medroxyprogesterone acetate (MPA), 1.5 mg
Number of subjects: 822
Study 17689624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 15453549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.25-4.0 mg per day)
Number of subjects: 65
Study 15453549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 11606148 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release sodium fluoride, calcium citrate, and cholecalciferol (SR-NaF group)
Number of subjects: 85
Study 11606148 — intervention group
Group type: COMPARATOR
Intervention: Calcium and cholecalciferol (control group)
Number of subjects: 85
Study 9613265 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol at 5 micrograms.ml‐1
Number of subjects: 60
Study 9613265 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol at 6 micrograms.ml‐1
Number of subjects: 60
Study 9613265 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol at 7 micrograms.ml‐1
Number of subjects: 60
Study 9613265 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol at 8 micrograms.ml‐1
Number of subjects: 60
Study 7983121 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty after patellectomy
Number of subjects: 19
Study 7983121 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty with intact patella (Control)
Number of subjects: 19
Study 2189430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine (ergoloid mesylates)
Number of subjects: 0
Study 2189430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 422738 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading regimen of 2600 mg ASA divided into two equal doses 4 hours apart
Number of subjects: 6
Study 422738 — intervention group
Group type: COMPARATOR
Intervention: Control group received 650 mg ASA every 4 hours for 48 hours
Number of subjects: 6
Study 31961048 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-enhancer cream
Number of subjects: 0
Study 31961048 — intervention group
Group type: COMPARATOR
Intervention: Branded cream control
Number of subjects: 0
Study 30804992 — intervention group
Group type: EXPERIMENTAL
Intervention: CareToy intervention
Number of subjects: 44
Study 30804992 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 44
Study 28082519 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Number of subjects: 232
Study 28082519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 25580697 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual definitions of pain flare
Number of subjects: 45
Study 25580697 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of pain flare (often sharp)
Number of subjects: 45
Study 25580697 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement with supplied definition of pain flare
Number of subjects: 45
Study 22781385 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg intravenously every 12 weeks
Number of subjects: 38
Study 22781385 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate 90 mg intravenously every 3 to 4 weeks (control)
Number of subjects: 38
Study 20658541 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposuspension
Number of subjects: 157
Study 20658541 — intervention group
Group type: COMPARATOR
Intervention: Anterior repair plus TVT
Number of subjects: 157
Study 20658541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 157
Study 20008710 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 3838
Study 20008710 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 3838
Study 20008710 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotics (given on the day of injection)
Number of subjects: 3838
Study 20008710 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotics (given after injection)
Number of subjects: 3838
Study 20008710 — intervention group
Group type: COMPARATOR
Intervention: Topical antibiotics (both before and after injection)
Number of subjects: 3838
Study 20008710 — intervention group
Group type: COMPARATOR
Intervention: No topical antibiotics
Number of subjects: 3838
Study 18020936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-Lane (FL)
Number of subjects: 451
Study 18020936 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-Lane with boosters (FL + B)
Number of subjects: 451
Study 18020936 — intervention group
Group type: COMPARATOR
Intervention: Diet-and-exercise attention-control (D&E)
Number of subjects: 451
Study 15499601 — intervention group
Group type: EXPERIMENTAL
Intervention: SIR-Spheres plus fluorouracil/leucovorin chemotherapy
Number of subjects: 21
Study 15499601 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil/leucovorin chemotherapy alone
Number of subjects: 21
Study 11573600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 150 IU ml(‐1)
Number of subjects: 90
Study 11573600 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase 15 IU ml(‐1)
Number of subjects: 90
Study 11573600 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine and 1% ropivacaine without hyaluronidase
Number of subjects: 90
Study 11573600 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine and 1% ropivacaine with hyaluronidase 15 IU ml(‐1)
Number of subjects: 90
Study 11573600 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine and 1% ropivacaine with hyaluronidase 150 IU ml(‐1)
Number of subjects: 90
Study 9745061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent sequential compression device
Number of subjects: 0
Study 9745061 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudopneumoperitoneum (PPP) model
Number of subjects: 0
Study 9745061 — intervention group
Group type: EXPERIMENTAL
Intervention: Real pneumoperitoneum (PP) at 14 mmHg
Number of subjects: 0
Study 9745061 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intraabdominal pressure
Number of subjects: 0
Study 7908076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 2316
Study 2575376 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to focus upon feared somatic sensations
Number of subjects: 30
Study 2575376 — intervention group
Group type: COMPARATOR
Intervention: Instructions to engage in distracting tasks
Number of subjects: 30
Study 1106218 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 1106218 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 0
Study 31542129 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes (0.4 mg nicotine/g tobacco)
Number of subjects: 240
Study 31542129 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 240
Study 31542129 — intervention group
Group type: COMPARATOR
Intervention: Very low nicotine content cigarettes (0.4 mg nicotine/g tobacco) with transdermal nicotine patch
Number of subjects: 240
Study 27935076 — intervention group
Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A
Number of subjects: 56